HomeGreater Than Icon
Mutual FundsGreater Than Icon
Compare Mutual FundsGreater Than Icon
Nippon India Pharma Fund - Direct (G) vs SBI Gilt Fund - Direct (G)

Nippon India Pharma Fund - Direct (G) vs SBI Gilt Fund - Direct (G)

stock1

Nippon India Pharma Fund - Direct (G)

7.97%

stock2

SBI Gilt Fund - Direct (G)

1.05%

Graph not available
Graph not available

About Fund

Deutsche Bank AG

Karvy Computershare Pvt. Ltd.

Citi Bank HDFC Bank Ltd. Stock Holding Corporation of India

Computer Age Management Services Pvt. Ltd Computronics Financial Services India Ltd Datamatics Financial Software Services Ltd

Very High Risk

5000

8306.35

1.12

550.4254

January 1, 2013

1

Moderate Risk

5000

9628.70

1.72

70.8555

January 1, 2013

0

14.49 %

22.06 %

7.97 %

6.05 %

6.62 %

1.05 %

Sailesh Raj Bhan

MBA (Finance), CFA.

Mr.Bhan is an MBA with specialization in Finance and CFA. Has over 9 Yrs. of experience in Equity Securities Research & Sequeir Investment Pvt. Ltd. for 5 years and with Emkay Share & stock Broker Pvt. Ltd. for 2 years.

Dinesh Ahuja

MBA From Mumbai University.

Having over 13 years of experience. Prior Assignments -Worked as fund manage in L&T Investment management Ltd amc, Reliance Capital Asset Management Ltd, Reliance General Insurance Company Ltd,ICAP Securities, Stratcap Securities and LKP Securities.

Rajeev Radhakrishnan

B.E. (Production), MMS (Finance), Cleared Level 2 of the CFA exam conducted by CFA Institute, USA.

Total experience of 17 years in funds management. Around 8 years in Fixed Income funds management and dealing. Previously he was associated with UTI Asset Management Company Ltd. as Co - Fund Manager Past experiences: SBI Funds Management P. Ltd - (From June 09, 2008 onwards) Co- Fund Manager - UTI Asset Management Company Limited (June 2001-2008)

Sudhir Agrawal

M.Com., PGDBA(Finance), CFA

Mr Sudhir Agrawal joined UTI AMC in 2009 after 8 years of experience. He has previously worked with CARE (Credit Analysis and Research Ltd.), Transparent Value LLC and Tata Asset Management Company Ltd in different roles. He is presently Fund Manager for UTI Treasury Advantage Fund, UTI Floating Rate Fund STP and UTI Short Term Income Fund.

Get your FAQs right

When comparing Nippon India Pharma Fund - Direct (G) vs SBI Gilt Fund - Direct (G), consider factors such as historical performance, expense ratios, investment strategy, risk level, and the fund manager's credibility. Moreover, look at asset allocation and how each fund fits your investment goals.
Yes, you can invest in both Nippon India Pharma Fund - Direct (G) and SBI Gilt Fund - Direct (G) at the same time. This can help diversify your portfolio and balance risk, provided the fund manager's investment strategies streamline each other.
While comparing Nippon India Pharma Fund - Direct (G) and SBI Gilt Fund - Direct (G), the portfolio turnover ratio indicates how frequently assets within the fund are bought and sold. A high turnover may lead to higher transaction costs and tax implications, while a low turnover ratio indicates a buy-and-hold strategy.
Yes, you can typically switch between Nippon India Pharma Fund - Direct (G) and SBI Gilt Fund - Direct (G), subject to the fund's policies and any applicable fees. It is important to consider potential tax implications and the timing of your switch.
Yes, you can compare Nippon India Pharma Fund - Direct (G) and SBI Gilt Fund - Direct (G) based on their dividend payouts. Look at dividends profit, consistency, and growth, as these factors can influence your overall return on investment.

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions